Drugs / Expanded , Activated NK cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02409576 | Feb 2015 → Aug 2020 | Ewing sarcoma, rhabdomyosarcoma | National University Hospital, Singapore | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Expanded , Activated NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02409576 ↗ |
| Modality | Cell therapy | “Infusions of allogeneic natural killer (NK) cells” NCT02409576 ↗ |
| Route | Intravenous | “Intravenous infusion of expanded, activated NK Cells” NCT02409576 ↗ |